WELLESLEY HILLS, Mass., March 21, 2011 /PRNewswire/ — Joseph F.
Finn, Jr., C.P.A. (“Finn”) Assignee for the Benefit of Creditors of
Source Precision Medicine, Inc. d/b/a/ Source MDx (“Source MDx”)
announced that the foundational patents of Source MDx will be
offered for sale on April 29, 2011.
Source MDx holds a broad-based, array of patents that cover
technical aspects of RNA transcript measurement, concepts
surrounding normal ranges in healthy human subjects (“normals”) and
statistical methods generating multi-gene models for the
discrimination of normals versus disease. Key patents
comprise the foundation of Source MDx’s intellectual property
portfolio. These include:
A. Systems and Methods for Characterizing a Biological
Condition or Agent using Precision Gene Expression (#6,692,916
issued 02.17.04)
B. Identification, Monitoring and Treatment of Disease and
Characterization of Biological Condition Using Gene Expression
Profiles (#6,940,439 issued 11.01.05)
C. Identification, Monitoring and Treatment of Disease and
Characterization of Biological Condition Using Gene Expression
Profiles (#6,964,850 pending)
Persons interested in bidding must sign a Confidentiality
Disclosure Agreement (“CDA”) obtained from Finn’s office –
jffinnjr@finnwarnkegayton or 781-27-8840. They will then
receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm
Finn, Warnke & Gayton LLP of Wellesley Hills, Massachusetts (www.finnwarnkegayton.com).
He works primarily in the area of management consulting for
distressed enterprises, bankruptcy accounting and related matters,
such as Assignee for the Benefit of Creditors and Liquidating Agent
for corporations. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-six (36) years. His
most recent
‘/>”/>
